PIMASERTIB AND SEROUS RETINAL DETACHMENTS
This is the first case that describes bilateral, multifocal central serous retinopathy appearing 2 days after starting pimasertib for ovarian cancer and rapidly resolving 3 days after stopping pimasertib. Pimasertib is an orally bioavailable MEK 1 and 2 inhibitor with potential antineoplastic activi...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Retinal Cases & Brief Reports
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890820/ |